Cargando…

Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences

BACKGROUND: Ketamine has recently received considerable attention regarding its antidepressant and anti-suicidal effects. Trials have generally focused on short-term effects of single intravenous infusions. Research on patient experiences is lacking. AIMS: To investigate the experiences over time of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lascelles, Karen, Marzano, Lisa, Brand, Fiona, Trueman, Hayley, McShane, Rupert, Hawton, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791565/
https://www.ncbi.nlm.nih.gov/pubmed/33283696
http://dx.doi.org/10.1192/bjo.2020.132
_version_ 1783633621911863296
author Lascelles, Karen
Marzano, Lisa
Brand, Fiona
Trueman, Hayley
McShane, Rupert
Hawton, Keith
author_facet Lascelles, Karen
Marzano, Lisa
Brand, Fiona
Trueman, Hayley
McShane, Rupert
Hawton, Keith
author_sort Lascelles, Karen
collection PubMed
description BACKGROUND: Ketamine has recently received considerable attention regarding its antidepressant and anti-suicidal effects. Trials have generally focused on short-term effects of single intravenous infusions. Research on patient experiences is lacking. AIMS: To investigate the experiences over time of individuals receiving ketamine treatment in a routine clinic, including impacts on mood and suicidality. METHOD: Twelve fee-paying patients with treatment-resistant depression (6 females, 6 males, age 21–70 years; 11 reporting suicidality and 6 reporting self-harm) who were assessed as eligible for ketamine treatment participated in up to three semi-structured interviews: before treatment started, a few weeks into treatment and ≥2 months later. Data were analysed thematically. RESULTS: Most participants hoped that ketamine would provide respite from their depression. Nearly all experienced improvement in mood following initial treatments, ranging from negligible to dramatic, and eight reported a reduction in suicidality. Improvements were transitory for most participants, although two experienced sustained consistent benefit and two had sustained but limited improvement. Some participants described hopelessness when treatment stopped working, paralleled by increased suicidal ideation for three participants. The transient nature and cost of treatment were problematic. Eleven participants experienced side-effects, which were significant for two participants. Suggestions for improving treatment included closer monitoring and adjunctive psychological therapy. CONCLUSIONS: Ketamine treatment was generally experienced as effective in improving mood and reducing suicidal ideation in the short term, but the lack of longer-term benefit was challenging for participants, as was treatment cost. Informed consent procedures should refer to the possibilities of relapse and associated increased hopelessness and suicidality.
format Online
Article
Text
id pubmed-7791565
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-77915652021-01-15 Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences Lascelles, Karen Marzano, Lisa Brand, Fiona Trueman, Hayley McShane, Rupert Hawton, Keith BJPsych Open Papers BACKGROUND: Ketamine has recently received considerable attention regarding its antidepressant and anti-suicidal effects. Trials have generally focused on short-term effects of single intravenous infusions. Research on patient experiences is lacking. AIMS: To investigate the experiences over time of individuals receiving ketamine treatment in a routine clinic, including impacts on mood and suicidality. METHOD: Twelve fee-paying patients with treatment-resistant depression (6 females, 6 males, age 21–70 years; 11 reporting suicidality and 6 reporting self-harm) who were assessed as eligible for ketamine treatment participated in up to three semi-structured interviews: before treatment started, a few weeks into treatment and ≥2 months later. Data were analysed thematically. RESULTS: Most participants hoped that ketamine would provide respite from their depression. Nearly all experienced improvement in mood following initial treatments, ranging from negligible to dramatic, and eight reported a reduction in suicidality. Improvements were transitory for most participants, although two experienced sustained consistent benefit and two had sustained but limited improvement. Some participants described hopelessness when treatment stopped working, paralleled by increased suicidal ideation for three participants. The transient nature and cost of treatment were problematic. Eleven participants experienced side-effects, which were significant for two participants. Suggestions for improving treatment included closer monitoring and adjunctive psychological therapy. CONCLUSIONS: Ketamine treatment was generally experienced as effective in improving mood and reducing suicidal ideation in the short term, but the lack of longer-term benefit was challenging for participants, as was treatment cost. Informed consent procedures should refer to the possibilities of relapse and associated increased hopelessness and suicidality. Cambridge University Press 2020-12-07 /pmc/articles/PMC7791565/ /pubmed/33283696 http://dx.doi.org/10.1192/bjo.2020.132 Text en © The Author(s) 2020 http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Papers
Lascelles, Karen
Marzano, Lisa
Brand, Fiona
Trueman, Hayley
McShane, Rupert
Hawton, Keith
Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences
title Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences
title_full Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences
title_fullStr Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences
title_full_unstemmed Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences
title_short Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences
title_sort ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences
topic Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791565/
https://www.ncbi.nlm.nih.gov/pubmed/33283696
http://dx.doi.org/10.1192/bjo.2020.132
work_keys_str_mv AT lascelleskaren ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences
AT marzanolisa ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences
AT brandfiona ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences
AT truemanhayley ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences
AT mcshanerupert ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences
AT hawtonkeith ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences